ADAP News and Press, Adaptimmune Therapeutics plc From 04/19/22

Shares of the small-cap cancer companies Adaptimmune Therapeutics (NASDAQ: ADAP) , Agenus (NASDAQ: AGEN) , and Sorrento Therapeutics (NASDAQ: SRNE) all rose by more than 5% during Tuesday's trading session. Adaptimmune, Agenus, and Sorrento appear to be getting a muc...

Shares of clinical-stage biopharmaceutical company Adaptimmune Therapeutics (NASDAQ: ADAP) fell 14.7% on Monday, dropping to $1.86. The stock has a 52-week low of $1.69 and a 52-week high of $6.86. Image source: Getty Images. The company specializes in using cell therapies t...

Adaptimmune Therapeutics (NASDAQ:ADAP) files for $400M mixed shelf securities of the registrant’s ADSs, warrants and units. Also files agreement prospectus supplement covering the offering, issuance and sale of up to $200M between the registrant and Cowen and company. Stock&#...

Adaptimmune Therapeutics (NASDAQ:ADAP) has filed for a $400M mixed shelf offering. Shares are down 5% in after-hours trading. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company will outline the use of proceeds in a prospectu...

- Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy - - Rate of eligible MAGE-A4 expression was 67% for synovial sarcoma, and ranged from 20%-35% for squamous cell lung, bladder, esophagogastric junction, ova...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Adaptimmune Therapeutics plc (ADAP) Q4 2021 Earnings Conference Call March 14, 2022 8:30 A.M. ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Elliot Norry - Chief Medical Office...

Adaptimmune press release (NASDAQ:ADAP): Q4 GAAP EPS of -$0.04 . Revenue of $1.4M (-6.7% Y/Y). As of December 31, 2021,the company had cash and cash equivalents of $149.9M Shares +7.14% PM. For further details see: Adaptimmune GAAP EPS of -$0.04, revenue of $1.4M

- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma - - Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated in esophageal and EGJ cancers; initiating SURPASS-3 in ovarian cancer in 2022 - - A...

ADAP, AVEO, BLDP, CORR, GOL, JAGX, LUNA, MTBC, PEI, PRTK For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open